INSERT INTO kol_info VALUES 
	('Michihiro Hide', 'chronic_urticaria', 'Department of Dermatology, Hiroshima University, Hiroshima, Japan; Department of Dermatology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.', 31.6, 9, 34, 19.0), 
	('Allen Kaplan', 'chronic_urticaria', 'Medical University of South Carolina, Charleston, SC, USA.', 87.4, 5, 27, 13.0), 
	('M Maurer', 'chronic_urticaria', 'Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany.', 101.2, 13, 56, 16.0), 
	('Karsten Weller', 'chronic_urticaria', 'Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany.', 102.0, 6, 30, 11.0), 
	('Karin Rosén', 'chronic_urticaria', 'Genentech, Inc, South San Francisco, Calif.', 109.6, 5, 25, 12.0), 
	('Sarbjit S Saini', 'chronic_urticaria', 'Johns Hopkins Asthma and Allergy Center, Baltimore, Maryland, USA.', 111.80000000000001, 4, 22, 13.0), 
	('Petra Staubach', 'chronic_urticaria', 'Department of Dermatology, University Medical Center, Mainz, Germany.', 112.2, 9, 48, 8.0), 
	('Sarbjit Saini', 'chronic_urticaria', 'Johns Hopkins Asthma and Allergy Center, Baltimore, Maryland, MD, USA.', 113.2, 3, 17, 13.0), 
	('Thomas B Casale', 'chronic_urticaria', 'University of South Florida, Tampa, Fla.', 113.80000000000001, 5, 24, 11.0), 
	('Karine Lheritier', 'chronic_urticaria', 'Novartis Pharma AG, Basel, Switzerland.', 114.6, 4, 24, 13.0), 
	('Martin Metz', 'chronic_urticaria', 'From the Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Berlin (M. Maurer, M. Metz), the Department of Dermatology, University Allergy Center, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden (A. Bauer), the Department of Dermatology, University Hospital Münster, Münster (R.B.), the Department of Dermatology, University Medical Center Mainz, Mainz (P.S.), and the Department of Dermatology and Allergy, Comprehensive Allergy Center, Hannover Medical School, Hannover (B.W.) - all in Germany; the Dermatology Department, Hospital del Mar-Institut Hospital del Mar d''Investigacions Mèdiques, Universitat Autònoma Barcelona, Barcelona (A.M.G.-A.); the Division of Allergy and Clinical Immunology, St. Michael''s Hospital and University of Toronto, Toronto (G.S.), Service d''Allergie, Centre Hospitalier Université Laval-Centre Hospitalier Universitaire de Québec, Quebec, QC (J.H.), and the Department of Medicine, University of Ottawa, Ottawa (K.K.) - all in Canada; Baker Allergy Asthma and Dermatology Clinic, Portland, OR (D.R.B.); University of Cincinnati College of Medicine, Department of Internal Medicine, Division of Immunology, Rheumatology, and Allergy and Bernstein Clinical Research Center, Cincinnati (J.A.B.); the Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine (C.-Y.C.), and the Department of Dermatology, Chang Gung Memorial Hospital (W.-H.C.), Taipei, Taiwan; the National Research Center-Institute of Immunology Federal Medical-Biological Agency of Russia, Moscow (I.D.), and the Department of Clinical Immunology and Allergology, Smolensk State Medical University, Smolensk (R.M.) - both in Russia; St. John''s Institute of Dermatology, Guy''s and St. Thomas'' Hospitals NHS Foundation Trust, London (C.G.), and the National Institute for Health Research-Leeds Biomedical Research Centre and Leeds Institute of Rheumatic and Musculoskeletal Medicine, and the Department of Clinical Immunology and Allergy, St. James''s University Hospital, Leeds (S.S.) - all in the United Kingdom; the School of Medicine, Western Sydney University, and the Immunology and Allergy Unit, Campbelltown Hospital, Campbelltown, NSW (C.K.), and Sinclair Dermatology and the Epworth Hospital, Melbourne, VIC (R.S.) - all in Australia; the Second Department of Dermatology and Venereology, Attikon University Hospital, Athens (M. Makris); Little Rock Allergy and Asthma Clinic, Little Rock, AR (K.S.); Novartis Pharma, Basel, Switzerland (J.L., T.S., R.J.); Novartis Pharmaceuticals, East Hanover, NJ (A. Barve, K.K.); and Shanghai Novartis Trading, Shanghai, China (E.H.).', 116.2, 10, 45, 11.0), 
	('Clive Grattan', 'chronic_urticaria', 'St John''s Institute of Dermatology, Guy''s and St Thomas'' Hospitals NHS Foundation Trust, London, UK.', 117.80000000000001, 3, 19, 12.0), 
	('Tomasz Hawro', 'chronic_urticaria', 'Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany.', 119.4, 6, 29, 11.0), 
	('Marta Ferrer', 'chronic_urticaria', 'Department of Allergy, Clinica Universidad de Navarra, Pamplona, Spain.', 134.4, 3, 20, 9.0), 
	('Benjamin Trzaskoma', 'chronic_urticaria', 'Genentech, Inc., South San Francisco, California, USA.', 137.8, 4, 20, 9.0), 
	('Randolf Brehler', 'chronic_urticaria', 'From the Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Berlin (M. Maurer, M. Metz), the Department of Dermatology, University Allergy Center, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden (A. Bauer), the Department of Dermatology, University Hospital Münster, Münster (R.B.), the Department of Dermatology, University Medical Center Mainz, Mainz (P.S.), and the Department of Dermatology and Allergy, Comprehensive Allergy Center, Hannover Medical School, Hannover (B.W.) - all in Germany; the Dermatology Department, Hospital del Mar-Institut Hospital del Mar d''Investigacions Mèdiques, Universitat Autònoma Barcelona, Barcelona (A.M.G.-A.); the Division of Allergy and Clinical Immunology, St. Michael''s Hospital and University of Toronto, Toronto (G.S.), Service d''Allergie, Centre Hospitalier Université Laval-Centre Hospitalier Universitaire de Québec, Quebec, QC (J.H.), and the Department of Medicine, University of Ottawa, Ottawa (K.K.) - all in Canada; Baker Allergy Asthma and Dermatology Clinic, Portland, OR (D.R.B.); University of Cincinnati College of Medicine, Department of Internal Medicine, Division of Immunology, Rheumatology, and Allergy and Bernstein Clinical Research Center, Cincinnati (J.A.B.); the Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine (C.-Y.C.), and the Department of Dermatology, Chang Gung Memorial Hospital (W.-H.C.), Taipei, Taiwan; the National Research Center-Institute of Immunology Federal Medical-Biological Agency of Russia, Moscow (I.D.), and the Department of Clinical Immunology and Allergology, Smolensk State Medical University, Smolensk (R.M.) - both in Russia; St. John''s Institute of Dermatology, Guy''s and St. Thomas'' Hospitals NHS Foundation Trust, London (C.G.), and the National Institute for Health Research-Leeds Biomedical Research Centre and Leeds Institute of Rheumatic and Musculoskeletal Medicine, and the Department of Clinical Immunology and Allergy, St. James''s University Hospital, Leeds (S.S.) - all in the United Kingdom; the School of Medicine, Western Sydney University, and the Immunology and Allergy Unit, Campbelltown Hospital, Campbelltown, NSW (C.K.), and Sinclair Dermatology and the Epworth Hospital, Melbourne, VIC (R.S.) - all in Australia; the Second Department of Dermatology and Venereology, Attikon University Hospital, Athens (M. Makris); Little Rock Allergy and Asthma Clinic, Little Rock, AR (K.S.); Novartis Pharma, Basel, Switzerland (J.L., T.S., R.J.); Novartis Pharmaceuticals, East Hanover, NJ (A. Barve, K.K.); and Shanghai Novartis Trading, Shanghai, China (E.H.).', 139.8, 5, 28, 13.0), 
	('Ana Gimenéz-Arnau', 'chronic_urticaria', 'Department of Dermatology, Institut Mar d''Investigacions Mediques, Universitat Autonoma, Barcelona, Spain.', 152.0, 2, 13, 12.0), 
	('Jasmin B Kuemmerle-Deschner', 'chronic_urticaria', 'University Hospital Tuebingen, Tuebingen, Germany.', 157.2, 4, 26, 14.0), 
	('Torsten Zuberbier', 'chronic_urticaria', NULL, 164.4, 4, 21, 7.0), 
	('Mary S Bradley', 'chronic_urticaria', 'Genentech, Inc, South San Francisco, Calif.', 174.0, 2, 14, 10.0), 
	('Kanokvalai Kulthanan', 'chronic_urticaria', 'Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.', 176.8, 5, 17, 7.0), 
	('Jonathan A Bernstein', 'chronic_urticaria', 'Division of Immunology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio.', 179.60000000000002, 11, 60, 9.0), 
	('Adriane Groffik', 'chronic_urticaria', 'Department of Dermatology, University Medical Center Mainz, Mainz, Germany.', 185.6, 2, 13, 11.0), 
	('Karoline Krause', 'chronic_urticaria', NULL, 187.0, 3, 14, 11.0), 
	('T Zuberbier', 'chronic_urticaria', NULL, 189.4, 5, 24, 15.0), 
	('Iñaki Izquierdo', 'chronic_urticaria', NULL, 193.2, 4, 20, 9.0), 
	('N Niimi', 'chronic_urticaria', NULL, 196.0, 3, 16, 17.0), 
	('Hsin-Ju Hsieh', 'chronic_urticaria', NULL, 197.0, 2, 12, 13.0), 
	('Janice Canvin', 'chronic_urticaria', NULL, 200.2, 2, 14, 10.0), 
	('Ana Giménez-Arnau', 'chronic_urticaria', NULL, 202.8, 5, 27, 7.0), 
	('Martin K Church', 'chronic_urticaria', NULL, 205.2, 3, 14, 11.0), 
	('Gordon Sussman', 'chronic_urticaria', 'From the Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Berlin (M. Maurer, M. Metz), the Department of Dermatology, University Allergy Center, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden (A. Bauer), the Department of Dermatology, University Hospital Münster, Münster (R.B.), the Department of Dermatology, University Medical Center Mainz, Mainz (P.S.), and the Department of Dermatology and Allergy, Comprehensive Allergy Center, Hannover Medical School, Hannover (B.W.) - all in Germany; the Dermatology Department, Hospital del Mar-Institut Hospital del Mar d''Investigacions Mèdiques, Universitat Autònoma Barcelona, Barcelona (A.M.G.-A.); the Division of Allergy and Clinical Immunology, St. Michael''s Hospital and University of Toronto, Toronto (G.S.), Service d''Allergie, Centre Hospitalier Université Laval-Centre Hospitalier Universitaire de Québec, Quebec, QC (J.H.), and the Department of Medicine, University of Ottawa, Ottawa (K.K.) - all in Canada; Baker Allergy Asthma and Dermatology Clinic, Portland, OR (D.R.B.); University of Cincinnati College of Medicine, Department of Internal Medicine, Division of Immunology, Rheumatology, and Allergy and Bernstein Clinical Research Center, Cincinnati (J.A.B.); the Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine (C.-Y.C.), and the Department of Dermatology, Chang Gung Memorial Hospital (W.-H.C.), Taipei, Taiwan; the National Research Center-Institute of Immunology Federal Medical-Biological Agency of Russia, Moscow (I.D.), and the Department of Clinical Immunology and Allergology, Smolensk State Medical University, Smolensk (R.M.) - both in Russia; St. John''s Institute of Dermatology, Guy''s and St. Thomas'' Hospitals NHS Foundation Trust, London (C.G.), and the National Institute for Health Research-Leeds Biomedical Research Centre and Leeds Institute of Rheumatic and Musculoskeletal Medicine, and the Department of Clinical Immunology and Allergy, St. James''s University Hospital, Leeds (S.S.) - all in the United Kingdom; the School of Medicine, Western Sydney University, and the Immunology and Allergy Unit, Campbelltown Hospital, Campbelltown, NSW (C.K.), and Sinclair Dermatology and the Epworth Hospital, Melbourne, VIC (R.S.) - all in Australia; the Second Department of Dermatology and Venereology, Attikon University Hospital, Athens (M. Makris); Little Rock Allergy and Asthma Clinic, Little Rock, AR (K.S.); Novartis Pharma, Basel, Switzerland (J.L., T.S., R.J.); Novartis Pharmaceuticals, East Hanover, NJ (A. Barve, K.K.); and Shanghai Novartis Trading, Shanghai, China (E.H.).', 207.20000000000002, 4, 25, 5.0), 
	('Leena Chularojanamontri', 'chronic_urticaria', 'Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.', 217.8, 3, 13, 7.0), 
	('Sabine Altrichter', 'chronic_urticaria', 'Dermatologial Allergology, Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Charitéplatz 1, Berlin, Germany; Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany; Berlin Institute of Health, Berlin, Germany.', 235.6, 2, 14, 13.0), 
	('P Staubach', 'chronic_urticaria', 'Department of Dermatology, University of Mainz, Mainz, Germany.', 237.6, 5, 21, 14.0), 
	('Evgeniya Antonova', 'chronic_urticaria', 'Genentech Inc, South San Francisco, California. Electronic address: antonova.evgeniya@gene.com.', 260.6, 2, 11, 9.0), 
	('Andrea Bauer', 'chronic_urticaria', 'From the Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Berlin (M. Maurer, M. Metz), the Department of Dermatology, University Allergy Center, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden (A. Bauer), the Department of Dermatology, University Hospital Münster, Münster (R.B.), the Department of Dermatology, University Medical Center Mainz, Mainz (P.S.), and the Department of Dermatology and Allergy, Comprehensive Allergy Center, Hannover Medical School, Hannover (B.W.) - all in Germany; the Dermatology Department, Hospital del Mar-Institut Hospital del Mar d''Investigacions Mèdiques, Universitat Autònoma Barcelona, Barcelona (A.M.G.-A.); the Division of Allergy and Clinical Immunology, St. Michael''s Hospital and University of Toronto, Toronto (G.S.), Service d''Allergie, Centre Hospitalier Université Laval-Centre Hospitalier Universitaire de Québec, Quebec, QC (J.H.), and the Department of Medicine, University of Ottawa, Ottawa (K.K.) - all in Canada; Baker Allergy Asthma and Dermatology Clinic, Portland, OR (D.R.B.); University of Cincinnati College of Medicine, Department of Internal Medicine, Division of Immunology, Rheumatology, and Allergy and Bernstein Clinical Research Center, Cincinnati (J.A.B.); the Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine (C.-Y.C.), and the Department of Dermatology, Chang Gung Memorial Hospital (W.-H.C.), Taipei, Taiwan; the National Research Center-Institute of Immunology Federal Medical-Biological Agency of Russia, Moscow (I.D.), and the Department of Clinical Immunology and Allergology, Smolensk State Medical University, Smolensk (R.M.) - both in Russia; St. John''s Institute of Dermatology, Guy''s and St. Thomas'' Hospitals NHS Foundation Trust, London (C.G.), and the National Institute for Health Research-Leeds Biomedical Research Centre and Leeds Institute of Rheumatic and Musculoskeletal Medicine, and the Department of Clinical Immunology and Allergy, St. James''s University Hospital, Leeds (S.S.) - all in the United Kingdom; the School of Medicine, Western Sydney University, and the Immunology and Allergy Unit, Campbelltown Hospital, Campbelltown, NSW (C.K.), and Sinclair Dermatology and the Epworth Hospital, Melbourne, VIC (R.S.) - all in Australia; the Second Department of Dermatology and Venereology, Attikon University Hospital, Athens (M. Makris); Little Rock Allergy and Asthma Clinic, Little Rock, AR (K.S.); Novartis Pharma, Basel, Switzerland (J.L., T.S., R.J.); Novartis Pharmaceuticals, East Hanover, NJ (A. Barve, K.K.); and Shanghai Novartis Trading, Shanghai, China (E.H.).', 264.2, 4, 20, 8.0), 
	('Jin-Moo Lee', 'chronic_urticaria', 'Department of Korean Gynecology, College of Korean Medicine, Kyung Hee University, Kyungheedae-ro, Dongdaemun-gu, Seoul.', 274.2, 3, 18, 10.0), 
	('M K Church', 'chronic_urticaria', 'Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany.', 280.6, 3, 17, 10.0), 
	('Papapit Tuchinda', 'chronic_urticaria', 'Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.', 289.6, 2, 11, 7.0), 
	('M Metz', 'chronic_urticaria', 'Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany.', 298.8, 4, 16, 9.0), 
	('James L Zazzali', 'chronic_urticaria', NULL, 301.0, 5, 19, 13.0), 
	('Ana Maria Gimenez-Arnau', 'chronic_urticaria', 'Department of Dermatology, Hospital del Mar-IMIM, Universitat Pompeu Fabra, Barcelona, Spain.', 309.8, 2, 14, 1.0), 
	('Koremasa Hayama', 'chronic_urticaria', 'Division of Cutaneous Science, Department of Dermatology, Nihon University School of Medicine, Tokyo, Japan.', 328.4, 2, 14, 6.0), 
	('Mati Chuamanochan', 'chronic_urticaria', 'Pharmacoepidemiology and Statistics Research Center, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand.', 343.8, 4, 12, 4.0), 
	('Isabelle Koné-Paut', 'chronic_urticaria', 'CeRéMAIA, AP-HP, Bicêtre Hospital, University of Paris Sud, Le Kremlin-Bicêtre, France.', 359.0, 2, 13, 13.0), 
	('Patompong Ungprasert', 'chronic_urticaria', 'Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, Ohio, USA.', 367.0, 2, 10, 4.0), 
	('Surapon Nochaiwong', 'chronic_urticaria', 'Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand.', 367.20000000000005, 4, 12, 4.0), 
	('Michael Holden', 'chronic_urticaria', 'Genentech, Inc., South San Francisco, Calif.', 369.2, 3, 12, 7.0), 
	('Laia Curto-Barredo', 'chronic_urticaria', NULL, 369.8, 2, 10, 6.0);

INSERT INTO kol_pub_list VALUES 
	('Michihiro Hide', 'Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.'), 
	('Michihiro Hide', 'Sustained safety and efficacy of ligelizumab in patients with chronic spontaneous urticaria: A one-year extension study.'), 
	('Michihiro Hide', 'The effectiveness of montelukast for the treatment of anti-histamine-resistant chronic urticaria.'), 
	('Michihiro Hide', 'Long-term safety and efficacy of rupatadine in Japanese patients with itching due to chronic spontaneous urticaria, dermatitis, or pruritus: A 12-month, multicenter, open-label clinical trial.'), 
	('Michihiro Hide', 'Efficacy and safety of rupatadine in Japanese adult and adolescent patients with chronic spontaneous urticaria: A double-blind, randomized, multicenter, placebo-controlled clinical trial.'), 
	('Michihiro Hide', 'Efficacy and safety of omalizumab for the treatment of refractory chronic spontaneous urticaria in Japanese patients: Subgroup analysis of the phase 3 POLARIS study.'), 
	('Michihiro Hide', 'Efficacy and safety of omalizumab in Japanese and Korean patients with refractory chronic spontaneous urticaria.'), 
	('Michihiro Hide', 'Efficacy and safety of bilastine in Japanese patients with chronic spontaneous urticaria: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II/III study.'), 
	('Michihiro Hide', 'One-year safety and efficacy study of bilastine treatment in Japanese patients with chronic spontaneous urticaria or pruritus associated with skin diseases.'), 
	('Allen Kaplan', 'Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria.'), 
	('Allen Kaplan', 'The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria.'), 
	('Allen Kaplan', 'Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy.'), 
	('Allen Kaplan', 'Angioedema in the omalizumab chronic idiopathic/spontaneous urticaria pivotal studies.'), 
	('Allen Kaplan', 'A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria.'), 
	('M Maurer', 'Chronic spontaneous urticaria and internal parasites--a systematic review.'), 
	('M Maurer', 'Potential blood biomarkers in chronic spontaneous urticaria.'), 
	('M Maurer', 'H1-antihistamine-refractory chronic spontaneous urticaria: it''s worse than we thought - first results of the multicenter real-life AWARE study.'), 
	('M Maurer', 'Analysis of disease activity categories in chronic spontaneous/idiopathic urticaria.'), 
	('M Maurer', 'Interleukin-17 is a potential player and treatment target in severe chronic spontaneous urticaria.'), 
	('M Maurer', 'The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change.'), 
	('M Maurer', 'The use of a responder analysis to identify clinically meaningful differences in chronic urticaria patients following placebo- controlled treatment with rupatadine 10 and 20 mg.'), 
	('M Maurer', 'Omalizumab--an effective and safe treatment of therapy-resistant chronic spontaneous urticaria.'), 
	('M Maurer', 'Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial.'), 
	('M Maurer', 'Positive impact of omalizumab on angioedema and quality of life in patients with refractory chronic idiopathic/spontaneous urticaria: analyses according to the presence or absence of angioedema.'), 
	('M Maurer', 'Comparison of the efficacy of levocetirizine 5 mg and desloratadine 5 mg in chronic idiopathic urticaria patients.'), 
	('M Maurer', 'Omalizumab rapidly improves angioedema-related quality of life in adult patients with chronic spontaneous urticaria: X-ACT study data.'), 
	('M Maurer', 'Omalizumab substantially improves dermatology-related quality of life in patients with chronic spontaneous urticaria.'), 
	('Karsten Weller', 'Prevalence of chronic urticaria in children and adults across the globe: Systematic review with meta-analysis.'), 
	('Karsten Weller', 'The Urticaria Activity Score-Validity, Reliability, and Responsiveness.'), 
	('Karsten Weller', 'Efficacy and safety of on-demand versus daily rupatadine in chronic spontaneous urticaria: A randomized trial.'), 
	('Karsten Weller', 'Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control.'), 
	('Karsten Weller', 'Can on-demand non-sedating antihistamines improve urticaria symptoms? A double-blind, randomized, single-dose study.'), 
	('Karsten Weller', 'Angioedema Activity Score (AAS): A Valid and Reliable Tool to Use in Asian Patients.'), 
	('Karin Rosén', 'Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.'), 
	('Karin Rosén', 'Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria.'), 
	('Karin Rosén', 'Omalizumab response in patients with chronic idiopathic urticaria: Insights from the XTEND-CIU study.'), 
	('Karin Rosén', 'The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria.'), 
	('Karin Rosén', 'Effect of Omalizumab on Blood Basophil Counts in Patients with Chronic Idiopathic/Spontaneous Urticaria.'), 
	('Sarbjit S Saini', 'Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study.'), 
	('Sarbjit S Saini', 'Similar Efficacy with Omalizumab in Chronic Idiopathic/Spontaneous Urticaria Despite Different Background Therapy.'), 
	('Sarbjit S Saini', 'Effect of Omalizumab on Blood Basophil Counts in Patients with Chronic Idiopathic/Spontaneous Urticaria.'), 
	('Sarbjit S Saini', 'Evaluating the minimally important difference of the urticaria activity score and other measures of disease activity in patients with chronic idiopathic urticaria.'), 
	('Petra Staubach', 'An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria.'), 
	('Petra Staubach', 'Fenebrutinib in H<sub>1</sub> antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial.'), 
	('Petra Staubach', 'Ligelizumab in adolescents with chronic spontaneous urticaria: Results of a dedicated phase 2b randomized clinical trial supported with pharmacometric analysis.'), 
	('Petra Staubach', 'Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study.'), 
	('Petra Staubach', 'The Urticaria Activity Score-Validity, Reliability, and Responsiveness.'), 
	('Petra Staubach', 'Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin.'), 
	('Petra Staubach', 'A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria.'), 
	('Petra Staubach', 'Omalizumab normalizes the gene expression signature of lesional skin in patients with chronic spontaneous urticaria: A randomized, double-blind, placebo-controlled study.'), 
	('Petra Staubach', 'Responsiveness and minimal important difference of the urticaria control test.'), 
	('Sarbjit Saini', 'Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.'), 
	('Sarbjit Saini', 'Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.'), 
	('Sarbjit Saini', 'A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria.'), 
	('Thomas B Casale', 'Similar Efficacy with Omalizumab in Chronic Idiopathic/Spontaneous Urticaria Despite Different Background Therapy.'), 
	('Thomas B Casale', 'Omalizumab response in patients with chronic idiopathic urticaria: Insights from the XTEND-CIU study.'), 
	('Thomas B Casale', 'The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria.'), 
	('Thomas B Casale', 'Impact of omalizumab on patient-reported outcomes in chronic idiopathic urticaria: Results from a randomized study (XTEND-CIU).'), 
	('Thomas B Casale', 'Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control.'), 
	('Karine Lheritier', 'Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria.'), 
	('Karine Lheritier', 'Long-term safety and efficacy of canakinumab in cryopyrin-associated periodic syndrome: results from an open-label, phase III pivotal study in Japanese patients.'), 
	('Karine Lheritier', 'Safety and efficacy of canakinumab in Japanese patients with phenotypes of cryopyrin-associated periodic syndrome as established in the first open-label, phase-3 pivotal study (24-week results).'), 
	('Karine Lheritier', 'Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study.'), 
	('Martin Metz', 'Fenebrutinib in H<sub>1</sub> antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial.'), 
	('Martin Metz', 'The Urticaria Activity Score-Validity, Reliability, and Responsiveness.'), 
	('Martin Metz', 'Sustained safety and efficacy of ligelizumab in patients with chronic spontaneous urticaria: A one-year extension study.'), 
	('Martin Metz', 'Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin.'), 
	('Martin Metz', 'H<sub>1</sub>-antihistamine inhibition of histamine- and codeine-induced wheals does not predict response in chronic cold urticaria.'), 
	('Martin Metz', 'A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria.'), 
	('Martin Metz', 'Omalizumab normalizes the gene expression signature of lesional skin in patients with chronic spontaneous urticaria: A randomized, double-blind, placebo-controlled study.'), 
	('Martin Metz', 'Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control.'), 
	('Martin Metz', 'Responsiveness and minimal important difference of the urticaria control test.'), 
	('Martin Metz', 'Ligelizumab for Chronic Spontaneous Urticaria.'), 
	('Clive Grattan', 'Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.'), 
	('Clive Grattan', 'Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.'), 
	('Clive Grattan', 'Effects of a topical treatment with spleen tyrosine kinase inhibitor in healthy subjects and patients with cold urticaria or chronic spontaneous urticaria: Results of a phase 1a/b randomised double-blind placebo-controlled study.'), 
	('Tomasz Hawro', 'The Urticaria Activity Score-Validity, Reliability, and Responsiveness.'), 
	('Tomasz Hawro', 'H<sub>1</sub>-antihistamine inhibition of histamine- and codeine-induced wheals does not predict response in chronic cold urticaria.'), 
	('Tomasz Hawro', 'Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials.'), 
	('Tomasz Hawro', 'Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control.'), 
	('Tomasz Hawro', 'Symptomatic Dermographism: A Systematic Review of Treatment Options.'), 
	('Tomasz Hawro', 'Responsiveness and minimal important difference of the urticaria control test.'), 
	('Marta Ferrer', 'Predicting Chronic Spontaneous Urticaria Symptom Return After Omalizumab Treatment Discontinuation: Exploratory Analysis.'), 
	('Marta Ferrer', 'Efficacy and safety of on-demand versus daily rupatadine in chronic spontaneous urticaria: A randomized trial.'), 
	('Marta Ferrer', 'Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria.'), 
	('Benjamin Trzaskoma', 'Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria.'), 
	('Benjamin Trzaskoma', 'Similar Efficacy with Omalizumab in Chronic Idiopathic/Spontaneous Urticaria Despite Different Background Therapy.'), 
	('Benjamin Trzaskoma', 'Effect of Omalizumab on Blood Basophil Counts in Patients with Chronic Idiopathic/Spontaneous Urticaria.'), 
	('Benjamin Trzaskoma', 'Angioedema in the omalizumab chronic idiopathic/spontaneous urticaria pivotal studies.'), 
	('Randolf Brehler', 'Efficacy and safety of on-demand versus daily rupatadine in chronic spontaneous urticaria: A randomized trial.'), 
	('Randolf Brehler', 'Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin.'), 
	('Randolf Brehler', 'Omalizumab normalizes the gene expression signature of lesional skin in patients with chronic spontaneous urticaria: A randomized, double-blind, placebo-controlled study.'), 
	('Randolf Brehler', 'Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase.'), 
	('Randolf Brehler', 'Ligelizumab for Chronic Spontaneous Urticaria.'), 
	('Ana Gimenéz-Arnau', 'Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.'), 
	('Ana Gimenéz-Arnau', 'Similar Efficacy with Omalizumab in Chronic Idiopathic/Spontaneous Urticaria Despite Different Background Therapy.'), 
	('Jasmin B Kuemmerle-Deschner', 'Rapid and Sustained Long-Term Efficacy and Safety of Canakinumab in Patients With Cryopyrin-Associated Periodic Syndrome Ages Five Years and Younger.'), 
	('Jasmin B Kuemmerle-Deschner', 'Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes.'), 
	('Jasmin B Kuemmerle-Deschner', 'Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS).'), 
	('Jasmin B Kuemmerle-Deschner', 'Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study.'), 
	('Torsten Zuberbier', 'Prevalence of chronic urticaria in children and adults across the globe: Systematic review with meta-analysis.'), 
	('Torsten Zuberbier', 'Chronic inducible urticaria: A systematic review of treatment options.'), 
	('Torsten Zuberbier', 'Can on-demand non-sedating antihistamines improve urticaria symptoms? A double-blind, randomized, single-dose study.'), 
	('Torsten Zuberbier', 'Responsiveness and minimal important difference of the urticaria control test.'), 
	('Mary S Bradley', 'Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study.'), 
	('Mary S Bradley', 'A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria.'), 
	('Kanokvalai Kulthanan', 'Prevalence of concomitant angioedema in chronic spontaneous urticaria: A systematic review and meta-analysis.'), 
	('Kanokvalai Kulthanan', 'Cyclosporine for Chronic Spontaneous Urticaria: A Meta-Analysis and Systematic Review.'), 
	('Kanokvalai Kulthanan', 'Autologous serum skin test in chronic idiopathic urticaria: prevalence, correlation and clinical implications.'), 
	('Kanokvalai Kulthanan', 'Symptomatic Dermographism: A Systematic Review of Treatment Options.'), 
	('Kanokvalai Kulthanan', 'Angioedema Activity Score (AAS): A Valid and Reliable Tool to Use in Asian Patients.'), 
	('Jonathan A Bernstein', 'An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria.'), 
	('Jonathan A Bernstein', 'Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients With Chronic Idiopathic (Spontaneous) Urticaria: A Meta-analysis of ""Real-world"" Evidence.'), 
	('Jonathan A Bernstein', 'Benralizumab for Chronic Spontaneous Urticaria.'), 
	('Jonathan A Bernstein', 'Comparative Safety Profiles of Individual Second-Generation H1-Antihistamines for the Treatment of Chronic Urticaria: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.'), 
	('Jonathan A Bernstein', 'Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria.'), 
	('Jonathan A Bernstein', 'Sustained safety and efficacy of ligelizumab in patients with chronic spontaneous urticaria: A one-year extension study.'), 
	('Jonathan A Bernstein', 'Similar Efficacy with Omalizumab in Chronic Idiopathic/Spontaneous Urticaria Despite Different Background Therapy.'), 
	('Jonathan A Bernstein', 'Omalizumab response in patients with chronic idiopathic urticaria: Insights from the XTEND-CIU study.'), 
	('Jonathan A Bernstein', 'Impact of omalizumab on patient-reported outcomes in chronic idiopathic urticaria: Results from a randomized study (XTEND-CIU).'), 
	('Jonathan A Bernstein', 'The addition of zafirlukast to cetirizine improves the treatment of chronic urticaria in patients with positive autologous serum skin test results.'), 
	('Jonathan A Bernstein', 'Ligelizumab for Chronic Spontaneous Urticaria.'), 
	('Adriane Groffik', 'Efficacy and safety of on-demand versus daily rupatadine in chronic spontaneous urticaria: A randomized trial.'), 
	('Adriane Groffik', 'Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control.'), 
	('Karoline Krause', 'H<sub>1</sub>-antihistamine inhibition of histamine- and codeine-induced wheals does not predict response in chronic cold urticaria.'), 
	('Karoline Krause', 'Rupatadine 20 mg and 40 mg are Effective in Reducing the Symptoms of Chronic Cold Urticaria.'), 
	('Karoline Krause', 'Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control.'), 
	('T Zuberbier', 'Role of nonallergic hypersensitivity reactions in children with chronic urticaria.'), 
	('T Zuberbier', 'Effects of a pseudoallergen-free diet on chronic spontaneous urticaria: a prospective trial.'), 
	('T Zuberbier', 'Pseudoallergen-free diet in the treatment of chronic urticaria. A prospective study.'), 
	('T Zuberbier', 'Night-time sedating H1 -antihistamine increases daytime somnolence but not treatment efficacy in chronic spontaneous urticaria: a randomized controlled trial.'), 
	('T Zuberbier', 'Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study.'), 
	('Iñaki Izquierdo', 'Rupatadine is effective in the treatment of chronic spontaneous urticaria in children aged 2-11 years.'), 
	('Iñaki Izquierdo', 'Rupatadine 20 mg and 40 mg are Effective in Reducing the Symptoms of Chronic Cold Urticaria.'), 
	('Iñaki Izquierdo', 'Influence of food on the oral bioavailability of rupatadine tablets in healthy volunteers: a single-dose, randomized, open-label, two-way crossover study.'), 
	('Iñaki Izquierdo', 'Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study.'), 
	('N Niimi', 'Intravenous immunoglobulin in autoimmune chronic urticaria.'), 
	('N Niimi', 'Randomized double-blind study of cyclosporin in chronic ''idiopathic'' urticaria.'), 
	('N Niimi', 'Increasing the dose of cetirizine may lead to better control of chronic idiopathic urticaria: an open study of 21 patients.'), 
	('Hsin-Ju Hsieh', 'Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.'), 
	('Hsin-Ju Hsieh', 'A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria.'), 
	('Janice Canvin', 'Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study.'), 
	('Janice Canvin', 'Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy.'), 
	('Ana Giménez-Arnau', 'Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria.'), 
	('Ana Giménez-Arnau', 'Predicting Chronic Spontaneous Urticaria Symptom Return After Omalizumab Treatment Discontinuation: Exploratory Analysis.'), 
	('Ana Giménez-Arnau', 'Sustained safety and efficacy of ligelizumab in patients with chronic spontaneous urticaria: A one-year extension study.'), 
	('Ana Giménez-Arnau', 'H<sub>1</sub>-antihistamine inhibition of histamine- and codeine-induced wheals does not predict response in chronic cold urticaria.'), 
	('Ana Giménez-Arnau', 'Rupatadine 20 mg and 40 mg are Effective in Reducing the Symptoms of Chronic Cold Urticaria.'), 
	('Martin K Church', 'H<sub>1</sub>-antihistamine inhibition of histamine- and codeine-induced wheals does not predict response in chronic cold urticaria.'), 
	('Martin K Church', 'Rupatadine 20 mg and 40 mg are Effective in Reducing the Symptoms of Chronic Cold Urticaria.'), 
	('Martin K Church', 'Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control.'), 
	('Gordon Sussman', 'Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.'), 
	('Gordon Sussman', 'Fenebrutinib in H<sub>1</sub> antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial.'), 
	('Gordon Sussman', 'Omalizumab Re-Treatment and Step-Up in Patients with Chronic Spontaneous Urticaria: OPTIMA Trial.'), 
	('Gordon Sussman', 'Ligelizumab for Chronic Spontaneous Urticaria.'), 
	('Leena Chularojanamontri', 'Cyclosporine for Chronic Spontaneous Urticaria: A Meta-Analysis and Systematic Review.'), 
	('Leena Chularojanamontri', 'Symptomatic Dermographism: A Systematic Review of Treatment Options.'), 
	('Leena Chularojanamontri', 'Angioedema Activity Score (AAS): A Valid and Reliable Tool to Use in Asian Patients.'), 
	('Sabine Altrichter', 'An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria.'), 
	('Sabine Altrichter', 'Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase.'), 
	('P Staubach', 'H1-antihistamine-refractory chronic spontaneous urticaria: it''s worse than we thought - first results of the multicenter real-life AWARE study.'), 
	('P Staubach', 'Omalizumab--an effective and safe treatment of therapy-resistant chronic spontaneous urticaria.'), 
	('P Staubach', 'Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial.'), 
	('P Staubach', 'Autologous whole blood injections to patients with chronic urticaria and a positive autologous serum skin test: a placebo-controlled trial.'), 
	('P Staubach', 'Omalizumab rapidly improves angioedema-related quality of life in adult patients with chronic spontaneous urticaria: X-ACT study data.'), 
	('Evgeniya Antonova', 'Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria.'), 
	('Evgeniya Antonova', 'Angioedema in the omalizumab chronic idiopathic/spontaneous urticaria pivotal studies.'), 
	('Andrea Bauer', 'Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study.'), 
	('Andrea Bauer', 'Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin.'), 
	('Andrea Bauer', 'Omalizumab normalizes the gene expression signature of lesional skin in patients with chronic spontaneous urticaria: A randomized, double-blind, placebo-controlled study.'), 
	('Andrea Bauer', 'Ligelizumab for Chronic Spontaneous Urticaria.'), 
	('Jin-Moo Lee', 'Efficacy and safety of ucha-shinki-hwan on korean patients with cold hypersensitivity in the hands and feet: Study protocol clinical trial (SPIRIT Compliant).'), 
	('Jin-Moo Lee', 'The efficacy and safety of Danggui-Sayuk-Ga-Osuyu-Saenggang-tang on Korean patients with cold hypersensitivity in the hands: study protocol for a pilot, double-blind, randomized, placebo-controlled, parallel-group clinical trial.'), 
	('Jin-Moo Lee', 'Efficacy and safety of Korean red ginseng for cold hypersensitivity in the hands and feet: a randomized, double-blind, placebo-controlled trial.'), 
	('M K Church', 'Potential blood biomarkers in chronic spontaneous urticaria.'), 
	('M K Church', 'Interleukin-17 is a potential player and treatment target in severe chronic spontaneous urticaria.'), 
	('M K Church', 'Night-time sedating H1 -antihistamine increases daytime somnolence but not treatment efficacy in chronic spontaneous urticaria: a randomized controlled trial.'), 
	('Papapit Tuchinda', 'Cyclosporine for Chronic Spontaneous Urticaria: A Meta-Analysis and Systematic Review.'), 
	('Papapit Tuchinda', 'Symptomatic Dermographism: A Systematic Review of Treatment Options.'), 
	('M Metz', 'Potential blood biomarkers in chronic spontaneous urticaria.'), 
	('M Metz', 'Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial.'), 
	('M Metz', 'Autologous whole blood injections to patients with chronic urticaria and a positive autologous serum skin test: a placebo-controlled trial.'), 
	('M Metz', 'Omalizumab rapidly improves angioedema-related quality of life in adult patients with chronic spontaneous urticaria: X-ACT study data.'), 
	('James L Zazzali', 'Demonstrating measurement equivalence of the electronic and paper formats of the Urticaria Patient Daily Diary in patients with chronic idiopathic urticaria.'), 
	('James L Zazzali', 'Evaluating the minimally important difference of the urticaria activity score and other measures of disease activity in patients with chronic idiopathic urticaria.'), 
	('James L Zazzali', 'Validity and responsiveness of the Urticaria Activity and Impact Measure: A new patient-reported tool.'), 
	('James L Zazzali', 'Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy.'), 
	('James L Zazzali', 'Angioedema in the omalizumab chronic idiopathic/spontaneous urticaria pivotal studies.'), 
	('Ana Maria Gimenez-Arnau', 'Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.'), 
	('Ana Maria Gimenez-Arnau', 'Efficacy and safety of on-demand versus daily rupatadine in chronic spontaneous urticaria: A randomized trial.'), 
	('Koremasa Hayama', 'Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria.'), 
	('Koremasa Hayama', 'Identification of biomarkers for predicting the response to cyclosporine A therapy in patients with chronic spontaneous urticaria.'), 
	('Mati Chuamanochan', 'Comparative Efficacy and Acceptability of Licensed Dose Second-Generation Antihistamines in Chronic Spontaneous Urticaria: A Network Meta-Analysis.'), 
	('Mati Chuamanochan', 'Comparative Safety Profiles of Individual Second-Generation H1-Antihistamines for the Treatment of Chronic Urticaria: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.'), 
	('Mati Chuamanochan', 'Evaluation of Pharmacologic Treatments for H1 Antihistamine-Refractory Chronic Spontaneous Urticaria: A Systematic Review and Network Meta-analysis.'), 
	('Mati Chuamanochan', 'Impact of Pharmacological Treatments for Chronic Spontaneous Urticaria with an Inadequate Response to H1-Antihistamines on Health-Related Quality of Life: A Systematic Review and Network Meta-Analysis.'), 
	('Isabelle Koné-Paut', 'Rapid and Sustained Long-Term Efficacy and Safety of Canakinumab in Patients With Cryopyrin-Associated Periodic Syndrome Ages Five Years and Younger.'), 
	('Isabelle Koné-Paut', 'Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study.'), 
	('Patompong Ungprasert', 'Prevalence of concomitant angioedema in chronic spontaneous urticaria: A systematic review and meta-analysis.'), 
	('Patompong Ungprasert', 'Symptomatic Dermographism: A Systematic Review of Treatment Options.'), 
	('Surapon Nochaiwong', 'Comparative Efficacy and Acceptability of Licensed Dose Second-Generation Antihistamines in Chronic Spontaneous Urticaria: A Network Meta-Analysis.'), 
	('Surapon Nochaiwong', 'Comparative Safety Profiles of Individual Second-Generation H1-Antihistamines for the Treatment of Chronic Urticaria: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.'), 
	('Surapon Nochaiwong', 'Evaluation of Pharmacologic Treatments for H1 Antihistamine-Refractory Chronic Spontaneous Urticaria: A Systematic Review and Network Meta-analysis.'), 
	('Surapon Nochaiwong', 'Impact of Pharmacological Treatments for Chronic Spontaneous Urticaria with an Inadequate Response to H1-Antihistamines on Health-Related Quality of Life: A Systematic Review and Network Meta-Analysis.'), 
	('Michael Holden', 'Omalizumab response in patients with chronic idiopathic urticaria: Insights from the XTEND-CIU study.'), 
	('Michael Holden', 'The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria.'), 
	('Michael Holden', 'Impact of omalizumab on patient-reported outcomes in chronic idiopathic urticaria: Results from a randomized study (XTEND-CIU).'), 
	('Laia Curto-Barredo', 'H<sub>1</sub>-antihistamine inhibition of histamine- and codeine-induced wheals does not predict response in chronic cold urticaria.'), 
	('Laia Curto-Barredo', 'Rupatadine 20 mg and 40 mg are Effective in Reducing the Symptoms of Chronic Cold Urticaria.');
